stockrow
Monday 9 November 2026
Export STRO’s income statement to Excel — free account
Sutro Biopharma, Inc.
STROSutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024.
- Revenue
- −84.6%
- EPS
- −66.4%
- Free cash flow
- +14.6%
Quarter to June 2026, against a year earlier
9.62
0.42
+4.57%
Follow STRO
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 2 | 3 | 5 | 3 | 2 | 1 | 4 | — | — |
P/S ratio |
0.96 | 2.29 | 1.79 | 6.00 | 11.09 | 16.55 | 5.91 | 1.35 | 0.00 | 0.00 |
Altman Z-Score |
(9.58) | (3.81) | (0.65) | (0.30) | 3.12 | 6.60 | 0.67 | (0.05) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.67 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(22.06) | (7.04) | (0.09) | 0.07 | 1.26 | 8.32 | (0.70) | 3.29 | (13.54) | (4.19) |
Beneish M-Score |
(3.10) | (4.15) | (0.20) | (4.51) | 13.25 | (2.41) | 3.15 | (2.89) | 1.86 | — |
P/Operating CF |
(3.72) | (1.98) | 19.54 | (17.05) | (31.80) | (37.46) | (19.20) | (8.75) | (0.52) | (0.52) |
P/B ratio |
0.00 | 3.19 | 1.84 | 1.87 | 2.72 | 2.13 | 2.58 | 0.39 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 3.19 | 1.84 | 1.87 | 2.72 | 2.13 | 2.58 | 0.39 | 0.00 | 0.00 |
EV/Sales |
(0.34) | (2.69) | (0.60) | 1.31 | 8.30 | 8.53 | 3.38 | (3.59) | 0.00 | 0.00 |
EV/EBITDA |
0.23 | 0.69 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 4.15 | 0.00 | 0.00 |
EV/Operating CF |
0.20 | 0.87 | 0.83 | 25.03 | (6.29) | (5.38) | (2.22) | (10.87) | 0.61 | 0.61 |
EV/FCF |
0.20 | 0.86 | 0.80 | (20.62) | (5.29) | (4.87) | (2.11) | (12.39) | 0.58 | 0.58 |
Quick Ratio |
1.94 | 2.47 | 4.39 | 5.13 | 5.04 | 12.63 | 3.77 | 5.68 | 0.74 | 0.96 |
Current Ratio |
2.01 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 | 0.99 |
Net Debt/EBITDA |
0.92 | 1.32 | 4.06 | 2.57 | 1.90 | 5.18 | 2.07 | 5.71 | 0.53 | (6.44) |
Debt/Assets |
0.00% | 0.00% | 0.86% | 4.00% | 7.36% | 6.23% | 6.32% | 6.60% | 35.72% | 1.72% |
Debt/Equity |
0.00 | 0.00 | 0.03 | 0.08 | 0.10 | 0.07 | 0.10 | 0.11 | (2.24) | 0.10 |
Asset Turnover |
0.37 | 0.14 | 0.35 | 0.18 | 0.17 | 0.16 | 0.23 | 0.29 | 0.94 | 1.08 |
Operating CF/Net income |
0.93 | 0.84 | 1.05 | (0.03) | 0.77 | 2.11 | 1.17 | (0.36) | 1.88 | (7.73) |
Capex/Depreciation |
(0.44) | 1.24 | 1.91 | (1.48) | (2.01) | (1.49) | (1.05) | (0.39) | (0.65) | (0.75) |
Interest Coverage |
(4.14) | (7.67) | (7.99) | (38.54) | (31.41) | (17.88) | (12.75) | 128.36 | (27.97) | 5.43 |
| 435.02% | (234.19%) | (58.25%) | (50.77%) | (36.11%) | (14.95%) | (48.62%) | (313.40%) | 19.70% | (1.70%) | |
| (68.12%) | (53.02%) | (24.34%) | (31.86%) | (28.70%) | (11.67%) | (29.38%) | (26.76%) | (35.78%) | 3.09% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (77.22%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(221.06%) | (99.07%) | (30.54%) | (38.30%) | (52.95%) | (8.89%) | (52.97%) | (19.15%) | (256.69%) | 9.35% |
Average Days of Receivables |
14.16 | 50.69 | 85.66 | 38.36 | 73.46 | 47.49 | 53.79 | 23.65 | 11.46 | 3.53 |
Research and Development Expense of Revenue |
162.38% | 406.24% | 117.36% | 202.40% | 168.71% | 180.14% | 153.53% | 141.24% | 105.60% | 72.91% |
Selling, General and Administrative Expense of Revenue |
40.02% | 78.10% | 40.71% | 87.86% | 90.50% | 86.18% | 76.26% | 55.65% | 31.65% | 24.81% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
13.67% | 39.79% | 16.20% | 38.81% | 37.56% | 27.89% | 24.13% | 7.48% | 2.69% | 1.62% |
Graham Net Nets |
(1.58) | 0.00 | 0.37 | 0.40 | 0.19 | 0.45 | 0.28 | 2.28 | 6.84 | 6.84 |
Graham Number |
88.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(194.93%) | (164.13%) | (38.95%) | (29.55%) | (15.39%) | (3.96%) | (22.00%) | (68.23%) | (5.20%) | (5.20%) |
Free Cash Flow Yield |
(181.98%) | (136.73%) | (42.16%) | (1.06%) | (14.14%) | (10.60%) | (27.13%) | 21.42% | (959.93%) | (959.93%) |
Revenue per Share |
12.06 | 8.02 | 25.55 | 13.36 | 13.42 | 13.12 | 18.61 | 66.71 | 1,154.93 | 1,464.00 |
Operating CF per Share |
(20.86) | (24.76) | (18.55) | 0.70 | (17.71) | (20.82) | (28.32) | 22.02 | (827.52) | (322.38) |
Capex per Share |
(0.20) | (0.40) | (0.72) | (1.55) | (3.32) | (2.19) | (1.52) | (2.70) | (74.02) | (107.30) |
Free Cash Flow per Share |
(21.06) | (25.16) | (19.27) | (0.85) | (21.03) | (23.00) | (29.84) | 19.32 | (901.54) | (429.68) |
Cash per Share |
16.64 | 40.96 | 62.43 | 65.90 | 42.92 | 113.02 | 51.34 | 355.08 | 491.52 | 1,164.73 |
Shareholders Equity per Share |
(15.59) | 5.76 | 24.87 | 42.78 | 54.76 | 101.94 | 42.59 | 228.41 | (145.00) | 284.83 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(15.59) | 5.76 | 24.87 | 42.78 | 54.76 | 101.94 | 42.59 | 228.41 | (145.00) | 284.83 |
Free Cash Flow |
(178.93) | (194.64) | (115.93) | (4.31) | (97.00) | (74.93) | (68.50) | 11.13 | (40.39) | (17.53) |
Working Capital |
75.79 | 211.42 | 327.80 | 286.61 | 176.78 | 348.59 | 95.60 | 173.52 | (6.33) | (0.49) |
Capital Expenditures |
(1.69) | (3.10) | (4.31) | (7.86) | (15.32) | (7.13) | (3.48) | (1.56) | (3.32) | (4.38) |
Net Current Asset Value |
(155.36) | 0.70 | 100.46 | 163.26 | 129.67 | 316.12 | 69.99 | 118.35 | (21.64) | (7.98) |
EV/EBIT |
0.22 | 0.70 | 1.04 | 0.00 | 0.00 | 0.00 | 0.00 | 3.70 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.05 | 0.03 | 0.12 | 0.25 | 0.17 | 0.08 | 0.04 | 0.06 | 0.07 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.37 | (0.14) | (0.10) | 0.22 | 0.34 | 0.37 | 0.34 | 0.37 | 0.36 | 0.31 |
Cash ROIC |
(1,993.38%) | (53.84%) | (21.90%) | (0.76%) | (20.40%) | (10.34%) | (30.37%) | 3.17% | (134.24%) | (29.06%) |
Accounts Receivable Turnover |
16.28 | 2.78 | 7.12 | 6.92 | 6.87 | 7.21 | 9.73 | 18.68 | 47.02 | 54.28 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
6.30 | 22.35 | 21.60 | 9.79 | 9.01 | 5.93 | 4.39 | 2.06 | 1.10 | 1.10 |
Average Payables |
9.02 | 9.96 | 7.12 | 5.40 | 5.78 | 5.56 | 4.32 | 2.98 | 3.15 | 3.15 |
Average Assets |
280.52 | 428.97 | 438.84 | 374.18 | 367.76 | 275.24 | 189.75 | 131.95 | 55.02 | 55.13 |
Average Common Equity |
(43.93) | 97.12 | 183.35 | 234.81 | 292.31 | 214.92 | 114.66 | 11.27 | (99.94) | (99.84) |
Columns are period end dates